Drug – bio-affecting and body treating compositions – Radionuclide or intended radionuclide containing; adjuvant... – In an organic compound
Patent
1996-10-04
2000-02-01
Feisee, Lila
Drug, bio-affecting and body treating compositions
Radionuclide or intended radionuclide containing; adjuvant...
In an organic compound
530300, 530326, 436808, 514 54, 534 10, 534 14, A61K 3800, A61K 5100, C07F 1300
Patent
active
06019958&
DESCRIPTION:
BRIEF SUMMARY
BACKGROUND OF THE INVENTION
1. Field of the Invention
This invention relates to compositions that are radiolabeled scintigraphic imaging agents, methods of using these compositions and methods for producing such radiolabeled compositions. Specifically, the invention relates to technetium-99m labeled scintigraphic imaging agents that are compositions of a polysulfated glycan or mixture thereof and a compound comprising a polybasic moiety covalently linked to a radiolabel binding moiety radiolabeled with technetium-99m (Tc-99m). Methods and kits for making such compositions, and methods for using such compositions to image sites of infection and inflammation in a mammalian body are also provided.
2. Description of the Prior Art
There is a clinical need to be able to determine the location and/or extent of sites of focal or localized infection and inflammation. In a substantial number of cases conventional methods of diagnosis (such as physical examination, x-ray, CT and ultrasonography) fail to identify such sites (e.g., an abscess). Although biopsy may be resorted to, it is preferable to avoid such invasive procedures, at least until they are diagnostically appropriate to identify the pathogen responsible for an abscess at a known location. Identifying the site of such "occult" infection is important because rapid localization and identification of the problem is critical to effective therapeutic intervention.
In the field of nuclear medicine, certain pathological conditions can be localized or the extent of such conditions determined by imaging the internal distribution of administered radioactively-labeled tracer compounds (i.e. radiotracers or radiopharmaceuticals) that accumulate specifically at the pathological site. A variety of radionuclides are known to be useful for radioimaging, including .sup.67 Ga, .sup.99m Tc (Tc-99m), .sup.111 In, .sup.123 I, .sup.125 I, .sup.169 Yb and .sup.186 Re.
However, an abscess may be caused by any one of many possible pathogens, so that a radiotracer specific for a particular pathogen would have limited scope. On the other hand, infection is almost invariably accompanied by inflammation, which is a general response of the body to tissue injury. Therefore, a radiotracer specific for sites of inflammation would be expected to be useful in localizing sites of infection caused by any pathogen, as well as being useful for localizing other inflammatory sites.
One of the main phenomena associated with inflammation is the localization of leukocytes (white blood cells), usually monocytes and neutrophils, at the site of inflammation. A radiotracer specific for leukocytes would be useful in detecting leukocytes at the site of a localized infection. Currently approved nuclear medicine procedures for imaging sites of infection use either indium-111 labeled leukocytes (.sup.111 In-WBC) (see, e.g. Peters, 1992, J. Nucl. Med. 33: 65-67) or gallium-67 (.sup.67 Ga) citrate (see, e.g. Ebright et al., 1982, Arch. Int. Med. 142: 246-254). A major disadvantage of using .sup.111 In-labeled WBCs is that the preparation of the radiotracer requires a number of technical steps: sterile removal of autologous blood, sterile isolation of the leukocytes from the blood, sterile labeling of the leukocytes using conditions that do not damage the cells (since damaged WBC are taken up by the reticuloendothelial system when re-injected) and sterile return (re-injection) of the (now labeled) leukocytes to the patient. Furthermore, a delay of 12 to 48 hours between injection and imaging may be required to obtain optimum imaging. While Tc-99m labeled leukocytes have been used to shorten this delay period (see, e.g. Vorne et al., 1989, J. Nucl. Med. 30: 1332-1336), ex-corporeal labeling is still required. A preferred radiotracer would be one that either would label leukocyes in whole blood or would not require removal and manipulation of autologous blood components ex corpora.
Alternatively, .sup.67 Ga-citrate can be administered by intravenous injection. However, this compound is not specific for sites of
REFERENCES:
patent: 4057617 (1977-11-01), Abramovici et al.
patent: 4385046 (1983-05-01), Milbrath et al.
patent: 4434151 (1984-02-01), Byrne et al.
patent: 4444690 (1984-04-01), Fritzberg et al.
patent: 4472509 (1984-09-01), Gansow et al.
patent: 4571430 (1986-02-01), Byrne et al.
patent: 4575556 (1986-03-01), Byrne et al.
patent: 4578079 (1986-03-01), Ruoslhati et al.
patent: 4792525 (1988-12-01), Ruoslhati et al.
patent: 4857508 (1989-08-01), Adams et al.
patent: 4861869 (1989-08-01), Nicolotti et al.
patent: 4877868 (1989-10-01), Reno et al.
patent: 4935223 (1990-06-01), Phillips
patent: 4952562 (1990-08-01), Klein et al.
patent: 4986979 (1991-01-01), Morgan et al.
patent: 5086069 (1992-02-01), Klein et al.
patent: 5198424 (1993-03-01), McEver
patent: 5266562 (1993-11-01), Mukherjee et al.
patent: 5308603 (1994-05-01), Thakar
patent: 5376356 (1994-12-01), Morgan, Jr.
patent: 5561220 (1996-10-01), Dean et al.
Ronco et al. (1991) Int. J. Artif. Organs 14:457-462.
Baidoo et al., "Synthesis of a Diaminedithiol Bifunctional Chelating Agent for Incorporation of Technetium-99m Into Biomolecules," Bioconjugate Chemistry 1(2):132-137 (1990).
Bebawy et al., "In Vitro Effect of Platelet Factor 4 on Normal Human Neutrophil Functions," 1986, J. Leukocyte Biol. 39:423-434.
Ben-Haim et al., "The Safety and Pharmacokinetics in Adult Subjects of an Intravenously Administered .sup.99m Tc-labeled 17 Amino Acid Peptide (CYT-379)," Nucl. Med. Biol. 21(2): 131-142 (1994).
Bryson et al., 1988, "Neutral Technetium(V) Complexes with Amide-Thiol-Thioether Chelating Ligands", Inorg. Chem. 27:2154-2161.
Bryson et al., 1990, "Protecting Groups in the Preparation of Thiolate Complexes of Technetium", Inorg. Chem. 29:2948-2951.
Byrne and Tolman, 1983, "Technetium-99m Bifunctional Chelating Agent--Thiolactone for Coupling to Biomolecules, N.sub.2 S.sub.2 Ligand for Chelatoin to Technetium", J. Nucl. Med. 24:P126.
Yamamura, "Preparation of cysteine-containing pentapeptide as a ligand for peptide-metal complexes," Chemical Abstracts 114:850, abstract No. 186080b (1991).
Davison et al., 1981, "A New Class of Oxotechnetium(5+) Chelate Complexes containing a TcON.sub.2 S.sub.2 Core", Inorg. Chem. 20: 1629-1632.
Deuel et al., "Amino Acid sequence of human platelet factor 4," 1977, Proc. Natl. Acad. Sci. USA 74: 2256-2258.
Deuel et al., "Platelet factor 4 is chemotactic for neutrophils and monocytes," 1981, Proc. Natl. Acad. Sci. USA 78:4584-4587.
Ebright et al., "The gallium scan: Problems and misuse in examination of patients with suspected infections," Arch. Int. Med. 142:246-254 (1982).
Fischman et al., "Imaging Focal Sites of Bacerial Infection in Rats with Indium-111-Labeled Chemotactic Peptide Analogs," 1991, J. Nucl. Med. 32:482-491.
Fritzberg et al., 1982, "Clinical comparison of Tc-99m N,N',-bis(mercaptoacetamido)ethylenediamine and (.sup.131 I)ortho-iodohippurate for evaluation of renal tubular function: Concise Communication", J. Nucl. Med. 23:P17.
Fritzberg et al., 1982, "Synthesis and Biological Evaluation of Tc-99m N,N-Bix(mercaptoacetyl)-2,3-diaminopropanoate: A Potential Replacement for [.sup.131 I]o-iodohippurate", J. Nucl. Med. 23: 592-598.
Goldman et al., Inhibition of human neutrophil receptor-mediated uptake of N-Formyl-Met-Leu-Phe by platelet factor 4 (59-70), 1985, Immunol. 54: 163-171.
Hartman et al., 1992, "Non-peptide fibrinogen receptor antagonists: 1. Discovery and design of exosite inhibitors", J. Med. Chem. 35: 4640-4642.
Holt & Niewiarowski, "Biochemistry of .alpha. Granule Proteins," 1985, Sem. Hematol. 22: 151-163.
Jiang et al., "Localization of Abscess with an Iodinated Synthetic Chemotactic Peptide," 1982, Nuklearmedizin 21: 110-113.
Khaw et al., 1982, "Technetium-99m Labeling of Antibodies to Cardiac Myosin Fab and Human Fibrinogen", J. Nucl. Med. 23: 1011-1019.
Knight et al., "Evaluation of TC-99m Labeled Cyclic Peptides for Thrombus Imaging," The Journal of Nuclear Medicine 34(5):17P-18P (1993).
Knight et al., 1990, "Thrombus Imaging with Tc-99m Synthe
Dean Richard T.
Moyer Brian R.
Diatide, Inc.
Feisee Lila
McDaniels Patricia A.
Noonan Kevin E.
Pak Michael
LandOfFree
Technetium-99m labeled peptides for imaging inflammation does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Technetium-99m labeled peptides for imaging inflammation, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Technetium-99m labeled peptides for imaging inflammation will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-935103